NasdaqGS - Delayed Quote • USD
Scholar Rock Holding Corporation (SRRK)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 4:20 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 9 |
| Avg. Estimate | -0.51 | -0.51 | -2.06 | -1.93 |
| Low Estimate | -0.6 | -0.61 | -2.37 | -2.41 |
| High Estimate | -0.45 | -0.38 | -1.45 | -0.53 |
| Year Ago EPS | -0.49 | -0.47 | -1.99 | -2.06 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 9 |
| Avg. Estimate | -- | -- | -- | 28.7M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 90M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.58 | -0.55 | -0.52 | -0.49 |
| EPS Actual | -0.49 | -0.47 | -0.53 | -0.5 |
| Difference | 0.09 | 0.08 | -0.01 | -0.01 |
| Surprise % | 15.50% | 14.50% | -1.90% | -2.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.51 | -0.51 | -2.06 | -1.93 |
| 7 Days Ago | -0.51 | -0.51 | -2.06 | -1.93 |
| 30 Days Ago | -0.5 | -0.5 | -2.03 | -1.87 |
| 60 Days Ago | -0.48 | -0.48 | -1.91 | -1.68 |
| 90 Days Ago | -0.48 | -0.48 | -1.91 | -1.68 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 2 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SRRK | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -4.10% | -- | -- | 2.60% |
| Next Qtr. | -8.50% | -- | -- | 13.40% |
| Current Year | -3.50% | -- | -- | 5.20% |
| Next Year | 6.30% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Truist Securities: Buy to Buy | 4/3/2024 |
| Initiated | Raymond James: Strong Buy | 3/28/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 3/26/2024 |
| Reiterates | Truist Securities: Buy to Buy | 3/25/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/19/2024 |
| Upgrade | Jefferies: Hold to Buy | 10/25/2023 |
Related Tickers
GPCR Structure Therapeutics Inc.
38.98
+7.00%
VTYX Ventyx Biosciences, Inc.
4.0600
-4.25%
REPL Replimune Group, Inc.
6.15
-2.84%
BCYC Bicycle Therapeutics plc
22.52
-0.66%
STRO Sutro Biopharma, Inc.
3.4200
-1.44%
YMAB Y-mAbs Therapeutics, Inc.
14.84
-2.94%
SYRE Spyre Therapeutics, Inc.
32.47
-1.58%
RNA Avidity Biosciences, Inc.
23.83
-5.02%
KURA Kura Oncology, Inc.
19.00
+1.33%
THRD Third Harmonic Bio, Inc.
10.46
-7.68%